ADVANCED OVARIAN CANCER

After responding to platinum-based chemotherapyLYNPARZA is used as maintenance therapy to help prevent advanced ovarian cancer from growing or returning.

LYNPARZA is a non-chemotherapy treatment

Ovarian cancer is a disease in which cells multiply and grow abnormally. This type of cancer is prone to recurrence, which means it can become resistant to or return after chemotherapy, even if you have no evidence of detectable cancer cells in your body.

Maintenance therapy may make a difference

After chemotherapy, some doctors may choose to monitor you closely with tests and scans or prescribe maintenance therapy.

Maintenance therapy may help keep your advanced ovarian cancer from growing or returning after you have had a partial or complete response to a previous platinum-based chemotherapy.

Without maintenance therapy, advanced ovarian cancer may return in

Without maintenance treatment advanced ovarian cancer may return in about 7 out of 10 women within 3 years

about 7 out of 10 women within 3 years.*

*After surgery and their first line of chemotherapy.

LYNPARZA may help preserve the progress you've seen on chemotherapy

LYNPARZA is part of a proven 2-step plan to help keep your advanced ovarian cancer from growing or returning after platinum-based chemotherapy. LYNPARZA does not work in everyone. Scroll down to see clinical study results.

LYNPARZA may give you more time progression free

STEP 1

Treat your cancer with chemotherapy

Once you begin chemotherapy, ask your doctor what else you can do after responding to platinum-based chemotherapy. They may suggest LYNPARZA as a next step.

STEP 2

Preserve your progress with LYNPARZA

After chemotherapy, continue to help keep cancer from growing or returning with LYNPARZA—an oral maintenance therapy.

Talk to your doctor early about maintenance therapy with LYNPARZA

 

LYNPARZA may help preserve the progress you've seen on chemotherapy

LYNPARZA is part of a proven 2-step plan to help keep your advanced ovarian cancer from growing or returning after platinum-based chemotherapy. LYNPARZA does not work in everyone. Scroll down to see clinical study results.

LYNPARZA may give you more time progression free

STEP 1

Treat your cancer with chemotherapy

Once you begin chemotherapy, ask your doctor what else you can do after responding to platinum-based chemotherapy. They may suggest LYNPARZA as a next step.

STEP 2

Preserve your progress with LYNPARZA

After chemotherapy, continue to help keep cancer from growing or returning with LYNPARZA—an oral maintenance therapy.

Talk to your doctor early about maintenance therapy with LYNPARZA

 

LYNPARZA may help preserve the progress you've seen on chemotherapy

LYNPARZA is part of a proven 2-step plan to help keep your advanced ovarian cancer from growing or returning after platinum-based chemotherapy. LYNPARZA does not work in everyone. Scroll down to see clinical study results.

STEP 1

Treat your cancer with chemotherapy

Once you begin chemotherapy, ask your doctor what else you can do after responding to platinum-based chemotherapy. They may suggest LYNPARZA as a next step.

STEP 2

Preserve your progress with LYNPARZA

After chemotherapy, continue to help keep cancer from growing or returning with LYNPARZA—an oral maintenance therapy.

LYNPARZA may give you more time progression free
Talk to your doctor about LYNPARZA

Talk to your doctor early about maintenance therapy with LYNPARZA

 

BRCA mutations and LYNPARZA

LYNPARZA is for women with or without a BRCA mutation, depending on where you are in your treatment journey. If your doctor has confirmed you have a BRCA mutation, it may determine when you start treatment with LYNPARZA, so the sooner you get a genetic test after diagnosis, the better informed you and your doctor will be to help determine your treatment plan. National guidelines recommend genetic testing for all women with advanced ovarian cancer.

LEARN ABOUT GENETIC TESTING

LYNPARZA is prescribed for two groups of women with advanced ovarian cancer

After first-line chemotherapy

  • You’ve responded to your first line of platinum-based chemotherapy
  • You have a BRCA mutation confirmed by your doctor
SEE CLINICAL STUDY RESULTS

After second-line chemotherapy

  • Your advanced ovarian cancer has returned and you’ve responded to your second line of platinum-based chemotherapy
  • You may or may not have a BRCA mutation
SEE CLINICAL STUDY RESULTS

LYNPARZA was tested against placebo in several advanced ovarian cancer clinical studies, shown below. Placebo is a pill that doesn’t contain any active medication and does not treat cancer.

LYNPARZA could give you MORE TIME progression free

CLINICAL STUDY RESULTS

After first-line chemotherapy

Women with a BRCA mutation

The SOLO-1 study tested 391 women with a BRCA mutation and advanced ovarian cancer after they responded to first-line platinum-based chemotherapy. 260 women took LYNPARZA and 131 took placebo.

LYNPARZA lowered the risk of disease progression or death by 70% compared to placebo in the SOLO-1 Study

LYNPARZA lowered the risk of disease progression or death by 70% compared to placebo.

Most women (61%) taking LYNPARZA did not see their cancer grow or return at a median follow-up of 3.4 years (41 months).

LYNPARZA

158 out of 260 women

PLACEBO

35 out of 131 women

158 out of 260 women did not see their cancer grow or return at a median follow-up of 3.4 years (41 months) compared to 35 out of 131 women on placebo. Some women saw their cancer grow or return. This study is still ongoing, but the results at the time the data were assessed are shown above.

Watch Linda’s story

See how LYNPARZA can be used as a maintenance treatment.*

*Linda is not a real patient.

X


CLINICAL STUDY RESULTS

After second-line chemotherapy

The SOLO-2 study tested 295 women with an inherited BRCA mutation and advanced ovarian cancer that had returned and responded to platinum-based chemotherapy. 196 women took LYNPARZA and 99 women took placebo.

LYNPARZA lowered the risk of cancer growing or returning by 70% compared to placebo in the SOLO-2 Study

LYNPARZA lowered the risk of disease progression or death by 70% compared to placebo.

Women on LYNPARZA didn’t see their cancer progress for a median of 1.5 years (19.1 months) vs 5.5 months on placebo.

LYNPARZA
PLACEBO

196 out of 295 women on LYNPARZA did not see their cancer grow or return for a median of more than 1.5 years (19.1 months), compared with 99 out of 295 women on placebo who did not see their cancer grow or return for a median of 5.5 months.

Study 19 tested 265 women with or without a BRCA mutation whose ovarian cancer had returned and responded to platinum-based chemotherapy. 136 women took LYNPARZA and 129 women took placebo.

LYNPARZA reduced the risk of disease progression or death by 65% compared to placebo.

Women on LYNPARZA didn’t see their cancer progress for a median of 8.4 months vs 4.8 months on placebo.

LYNPARZA
PLACEBO

136 out of 265 women on LYNPARZA did not see their cancer grow or return for a median of 8.4 months, compared with 129 out of 265 women on placebo who did not see their cancer grow or return for a median of 4.8 months.

LYNPARZA patient information

LYNPARZA patient information

The Ovarian Cancer Patient Brochure gives you more information on starting and continuing treatment with LYNPARZA.

DOWNLOAD BROCHURE

Future states

Downloadable resources

LYNPARZA patient information

Get more information on starting and continuing treatment with LYNPARZA.

DOWNLOAD Ovarian Cancer Patient Brochure

Tips for managing your treatment

Learn more about the potential side effects of LYNPARZA and how you should work with your doctor to manage them.

DOWNLOAD Tips for Managing Your Treatment Brochure

LYNPARZA caregivers

Our Caregiver Brochure provides useful tips and information. Learn more about the importance of looking after yourself as a caregiver.

DOWNLOAD LYNPARZA Caregiver Brochure

LYNPARZA dosing

Find out all about taking LYNPARZA and how to make it part of your daily routine.

DOWNLOAD LYNPARZA Dosing Brochure

Downloadable resources

LYNPARZA patient information

Get more information on starting and continuing treatment with LYNPARZA.

DOWNLOAD Ovarian Cancer Patient Brochure

Tips for managing your treatment

Learn more about the potential side effects of LYNPARZA and how you should work with your doctor to manage them.

DOWNLOAD Tips for Managing Your Treatment Brochure

LYNPARZA caregivers

Our Caregiver Brochure provides useful tips and information. Learn more about the importance of looking after yourself as a caregiver.

DOWNLOAD LYNPARZA Caregiver Brochure

WHAT IS LYNPARZA?

LYNPARZA is a prescription medicine used to treat adults who have:

  • advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene. LYNPARZA is used alone as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy. Your healthcare provider will perform a test to make sure that LYNPARZA is right for you
  • ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, as maintenance treatment, when the cancer has come back. LYNPARZA is used after the cancer has responded to treatment with platinum-based chemotherapy
  • advanced ovarian cancer with a certain type of abnormal inherited BRCA gene, and have received treatment with 3 or more prior types of chemotherapy medicines. Your healthcare provider will perform a test to make sure that LYNPARZA is right for you

It is not known if LYNPARZA is safe and effective in children.

IMPORTANT SAFETY INFORMATION 

LYNPARZA may cause serious side effects, including: Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have ovarian cancer or breast cancer and who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with LYNPARZA. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with LYNPARZA.

Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily.

    Your healthcare provider will do blood tests to check your blood cell counts:
  • before treatment with LYNPARZA
  • every month during treatment with LYNPARZA
  • weekly if you have low blood cell counts that last a long time. Your healthcare provider may stop treatment with LYNPARZA until your blood cell counts improve

Lung problems (pneumonitis). Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may do a chest x-ray if you have any of these symptoms. Your healthcare provider may temporarily or completely stop treatment if you develop pneumonitis. Pneumonitis may lead to death.

    Before taking LYNPARZA, tell your healthcare provider about all of your medical conditions, including if you:
  • have lung or breathing problems
  • have kidney problems
  • are pregnant, become pregnant, or plan to become pregnant. LYNPARZA can harm your unborn baby and may cause loss of pregnancy (miscarriage)
    • If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with LYNPARZA
    • Females who are able to become pregnant should use effective birth control (contraception) during treatment with LYNPARZA and for 6 months after the last dose of LYNPARZA. Talk to your healthcare provider about birth control methods that may be right for you. Tell your healthcare provider right away if you become pregnant or think you might be pregnant following treatment with LYNPARZA
  • are breastfeeding or plan to breastfeed. It is not known if LYNPARZA passes into your breast milk. Do not breastfeed during treatment with LYNPARZA and for 1 month after receiving the last dose of LYNPARZA. Talk to your healthcare provider about the best way to feed your baby during this time

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking LYNPARZA and certain other medicines may affect how LYNPARZA works and may cause side effects.

    How should I take LYNPARZA?
  • Take LYNPARZA tablets exactly as your healthcare provider tells you
  • Do not change your dose or stop taking LYNPARZA unless your healthcare provider tells you to. Your healthcare provider may temporarily stop treatment with LYNPARZA or change your dose of LYNPARZA if you experience side effects
  • Your healthcare provider will decide how long you stay on treatment
  • Do not take more than 4 LYNPARZA tablets in 1 day. If you have any questions about LYNPARZA, talk to your healthcare provider or pharmacist
  • Take LYNPARZA by mouth 2 times a day
  • Each dose should be taken about 12 hours apart
  • Swallow LYNPARZA tablets whole. Do not chew, crush, dissolve, or divide the tablets
  • Take LYNPARZA with or without food
  • If you miss a dose of LYNPARZA, take your next dose at your usual scheduled time. Do not take an extra dose to make up for a missed dose
  • If you take too much LYNPARZA, call your healthcare provider or go to the nearest hospital emergency room right away

What should I avoid while taking LYNPARZA?Avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange juice during treatment with LYNPARZA since they may increase the level of LYNPARZA in your blood.

    LYNPARZA may cause serious side effects (see above). The most common side effects of LYNPARZA are:
  • nausea or vomiting. Tell your healthcare provider if you get nausea or vomiting. Your healthcare provider may prescribe medicines to treat these symptoms
  • tiredness or weakness
  • low red blood cell counts
  • diarrhea
  • loss of appetite
  • headache
  • low white blood cell counts
  • changes in the way food tastes
  • cough
  • shortness of breath
  • dizziness
  • indigestion or heartburn
  • low platelet counts
  • upper stomach area (abdominal) pain

These are not all the possible side effects of LYNPARZA. Call your healthcare provider for medical advice about side effects.

You may report side effects related to AstraZeneca products by clicking here. If you prefer to report these to the FDA, either visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

Please click here for complete Prescribing Information, including Patient Information (Medication Guide).

WHAT IS LYNPARZA?

LYNPARZA is a prescription medicine used to treat adults who have:

  • advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene. LYNPARZA is used alone as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy. Your healthcare provider will perform a test to make sure that LYNPARZA is right for you
  • ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, as maintenance treatment, when the cancer has come back. LYNPARZA is used after the cancer has responded to treatment with platinum-based chemotherapy
  • advanced ovarian cancer with a certain type of abnormal inherited BRCA gene, and have received treatment with 3 or more prior types of chemotherapy medicines. Your healthcare provider will perform a test to make sure that LYNPARZA is right for you

It is not known if LYNPARZA is safe and effective in children.

IMPORTANT SAFETY INFORMATION

LYNPARZA may cause serious side effects, including: Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have ovarian cancer or breast cancer and who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with LYNPARZA. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with LYNPARZA.

Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily.

    Your healthcare provider will do blood tests to check your blood cell counts:
  • before treatment with LYNPARZA
  • every month during treatment with LYNPARZA
  • weekly if you have low blood cell counts that last a long time. Your healthcare provider may stop treatment with LYNPARZA until your blood cell counts improve

Lung problems (pneumonitis). Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may do a chest x-ray if you have any of these symptoms. Your healthcare provider may temporarily or completely stop treatment if you develop pneumonitis. Pneumonitis may lead to death.

    Before taking LYNPARZA, tell your healthcare provider about all of your medical conditions, including if you:
  • have lung or breathing problems
  • have kidney problems
  • are pregnant, become pregnant, or plan to become pregnant. LYNPARZA can harm your unborn baby and may cause loss of pregnancy (miscarriage)
    • If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with LYNPARZA
    • Females who are able to become pregnant should use effective birth control (contraception) during treatment with LYNPARZA and for 6 months after the last dose of LYNPARZA. Talk to your healthcare provider about birth control methods that may be right for you. Tell your healthcare provider right away if you become pregnant or think you might be pregnant following treatment with LYNPARZA
  • are breastfeeding or plan to breastfeed. It is not known if LYNPARZA passes into your breast milk. Do not breastfeed during treatment with LYNPARZA and for 1 month after receiving the last dose of LYNPARZA. Talk to your healthcare provider about the best way to feed your baby during this time

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking LYNPARZA and certain other medicines may affect how LYNPARZA works and may cause side effects.

    How should I take LYNPARZA?
  • Take LYNPARZA tablets exactly as your healthcare provider tells you
  • Do not change your dose or stop taking LYNPARZA unless your healthcare provider tells you to. Your healthcare provider may temporarily stop treatment with LYNPARZA or change your dose of LYNPARZA if you experience side effects
  • Your healthcare provider will decide how long you stay on treatment
  • Do not take more than 4 LYNPARZA tablets in 1 day. If you have any questions about LYNPARZA, talk to your healthcare provider or pharmacist
  • Take LYNPARZA by mouth 2 times a day
  • Each dose should be taken about 12 hours apart
  • Swallow LYNPARZA tablets whole. Do not chew, crush, dissolve, or divide the tablets
  • Take LYNPARZA with or without food
  • If you miss a dose of LYNPARZA, take your next dose at your usual scheduled time. Do not take an extra dose to make up for a missed dose
  • If you take too much LYNPARZA, call your healthcare provider or go to the nearest hospital emergency room right away

What should I avoid while taking LYNPARZA?Avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange juice during treatment with LYNPARZA since they may increase the level of LYNPARZA in your blood.

    LYNPARZA may cause serious side effects (see above). The most common side effects of LYNPARZA are:
  • nausea or vomiting. Tell your healthcare provider if you get nausea or vomiting. Your healthcare provider may prescribe medicines to treat these symptoms
  • tiredness or weakness
  • low red blood cell counts
  • diarrhea
  • loss of appetite
  • headache
  • low white blood cell counts
  • changes in the way food tastes
  • cough
  • shortness of breath
  • dizziness
  • indigestion or heartburn
  • low platelet counts
  • upper stomach area (abdominal) pain

These are not all the possible side effects of LYNPARZA. Call your healthcare provider for medical advice about side effects.

You may report side effects related to AstraZeneca products by clicking here. If you prefer to report these to the FDA, either visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

Please click here for complete Prescribing Information, including Patient Information (Medication Guide).